Pacira Pharma (PCRX) Misses Q1 EPS by 104c

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of ($0.43), $1.04 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $160.3 million versus the consensus estimate of $159.1 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Benchmark Reiterates Hold Rating on Codexis, Inc. (CDXS) Amid Transition to New Products/Services
• Bernstein upgrades Analog Devices on Q3 beat, improving risk-reward